Active Filter(s):
Details:
The acquisitions are expected to enable Ligand to secure new license agreements with expanded economics as a result of the addition of tools and intellectual property that Ligand can now offer to partners.
Lead Product(s): Mono- and Bispecific human antibodies
Therapeutic Area: Oncology Product Name: OmniAb
Highest Development Status: Discovery Platform Product Type: Large molecule
Partner/Sponsor/Collaborator: Ligand Pharmaceuticals
Deal Size: $5.0 million Upfront Cash: $5.0 million
Deal Type: Acquisition September 10, 2020